MARKET

RDHL

RDHL

Redhill Biopharm
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.85
+0.29
+3.39%
Closed 13:00 11/27 EST
OPEN
8.72
PREV CLOSE
8.56
HIGH
9.00
LOW
8.59
VOLUME
291.68K
TURNOVER
--
52 WEEK HIGH
11.35
52 WEEK LOW
3.262
MARKET CAP
331.07M
P/E (TTM)
-4.9663
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Do Hedge Funds Love RedHill Biopharma Ltd (RDHL)?
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 817 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]
Insider Monkey · 2d ago
RedHill (RDHL) Expands Opaganib Manufacturing Capacity in US
Zacks · 2d ago
RedHill Biopharma expands U.S. based manufacturing capacity of opaganib
RedHill Biopharma ([[RDHL]] +3.6%) partners with two leading, U.S.-based manufacturers for large-scale manufacturing of Opaganib. These collaborations further advance ongoing preparations to support potential emergency use applications.This new collaborations follow
Seekingalpha · 4d ago
RedHill Biopharma Expands U.S.-Based Manufacturing Capacity Of Opaganib For COVID-19
RedHill Biopharma Expands U.S.-Based Manufacturing Capacity of Opaganib for COVID-19       TEL AVIV, Israel and RALEIGH, N.C., Nov. 25, 2020 /PRNewswire/ -- RedHill Biopharma
Benzinga · 4d ago
RedHill Biopharma to Present at Evercore ISI HealthCONx and Piper Sandler Healthcare Conferences
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it will present and participate at the following virtual conferences in December:
PR Newswire · 6d ago
Why RedHill Biopharma's Stock Is Trading Higher Today
RedHill Biopharma (NASDAQ: RDHL) shares are trading higher on Friday after the company reported the initiation of its Phase 3 study of RHB-204 for first-line treatment of pulmonary nontuberculous mycobacteria.
Benzinga · 11/20 16:51
RedHill Biopharma Initiates Phase 3 Study of RHB-204 for First-Line Treatment of NTM Disease
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or "the Company"), a specialty biopharmaceutical company, today announced that it has initiated its Phase 3 study to evaluate the safety and efficacy of RHB-204 as a potential first-line, stand-alone, oral treatment of pulmonary nontuberculous mycobacteria (NTM) disease caused by Mycobacterium avium Complex (MAC) – a rare disease for which there is no FDA-approved first-line therapy.
PR Newswire · 11/20 13:00
LB, YY, BERY and NKLA among premarket gainers
Phoenix New Media (FENG) +62% after announcing special distribution.Hudson Capital (HUSN) +37%.Aptevo Therapeutics (APVO) +31% following a disclosure that 42.5% shareholder Tang Capital Partners offered to buy the remaining shares for $50/share in cash.Corcept
Seekingalpha · 11/19 13:29
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of RDHL. Analyze the recent business situations of Redhill Biopharm through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average RDHL stock price target is 21.20 with a high estimate of 27.00 and a low estimate of 12.00.
EPS
Institutional Holdings
Institutions: 73
Institutional Holdings: 11.51M
% Owned: 30.77%
Shares Outstanding: 37.41M
TypeInstitutionsShares
Increased
20
512.45K
New
20
165.02K
Decreased
9
159.05K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.18%
Pharmaceuticals & Medical Research
+1.72%
Key Executives
Chairman/Chief Executive Officer/Director
Dror Ben-Asher
Chief Financial Officer
Micha Ben Chorin
Chief Operating Officer
Gilead Raday
Senior Vice President
Reza Fathi
Senior Vice President
Adi Frish
Chief Scientific Officer
June Almenoff
Other/Director
Rick Scruggs
Other
Guy Goldberg
Director
Giuseppe Cipriano
Director
Nicolas Weinstein
Independent Director
Shmuel Cabilly
Independent Director
Alla Felder
Independent Director
Kenneth Reed
Independent Director
Eric Swenden
Independent Director
Ofer Tsimchi
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About RDHL
RedHill Biopharma Ltd. is an Israel-based specialty biopharmaceutical company, primarily focused on the commercialization and development of proprietary drugs for the treatment of gastrointestinal diseases. The Company promotes the gastrointestinal drug Aemcolo in the United States (U.S.). Its key clinical late-stage development programs include: RHB-104, with positive results from a first Phase 3 study for Crohn's disease; RHB-204, with a planned pivotal Phase 3 study for pulmonary nontuberculous mycobacteria (NTM) infections; RHB-102 (Bekinda), with positive results from a Phase 3 study for acute gastroenteritis and gastritis and positive results from a Phase 2 study for IBS-D; ABC294640 (Yeliva), RHB-106, and RHB-107.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of RedHill Biopharma Ltd (ADR) stock information, including NASDAQ:RDHL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RDHL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RDHL stock methods without spending real money on the virtual paper trading platform.